Hospira announced the launch of Paricalcitol Injection, the generic version of AbbVie’s Zemplar Injection. Zemplar is a vitamin D analog indicated for secondary hyperparathyroidism due to chronic renal failure.
The biological effects of paricalcitol are mediated through binding of the vitamin D receptor, which results in the selective activation of the vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting parathyroid hormone synthesis and secretion.
Paricalcitol Injection is available as a 5mcg/mL concentration in 5mcg and 10mcg multi-dose vials, and as a 2mcg/mL concentration in 2mcg vials. Hospira has begun shipping the product.
For more information call (800) 615-0187 or visit Hospira.com.